Partnership of cardiologists with gene transfer therapy prescribers is essential to identifing patient-specific considerations that might influence risk for adverse cardiac events.
ACTION and the Academic Research Consortium (ARC) aimed to harmonize definitions of pediatric and CHD AEs for use in clinical trials, registries, and regulatory evaluation.
Individuals with Fontan circulation are at risk of late mortality from both cardiac and noncardiac causes. Despite the known risk of mortality, referral indications for advanced heart failure care vary
The results of an ACTION-wide survey of pediatric cardiology providers are detailed in the latest ACTION publication, Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD):
COVID 19 infection in children causes a hyper-inflammatory syndrome referred to as multisystem inflammatory syndrome in children (MIS-C). This ACTION publication, published June 2, 2021 in Pediatric Cardiology, provides a
ACTION defines and collects pediatric heart failure metrics to implement quality improvement initiatives. This study sought to describe medication use at the time of discharge for children admitted with acute
Establishing Baseline Metrics of Heart Failure Medication Use in Children Read More »
Right heart failure (RHF) after LVAD implantation can negatively impact a child’s transplant candidacy and survival. Successful LVAD outcomes require anticipation, prevention, early identification, and management of RHF, but there
Right Heart Failure Considerations in Pediatric VADs Read More »
"*" indicates required fields
Copyright © 2024 Advanced Cardiac Therapies Improving Outcomes Network
